YOLFTbeta
68

Cheng Du Sheng Nuo Biotec Co. Ltd. A

688117 · SHG · Healthcare / Drug Manufacturers - Specialty & Generic

14.21CNY-0.30 (-2.07%)

Price History

Full chart

Market Stats

Previous Close14.51
Open14.65
Day Range14.17 – 14.68
52-Week Range17.70 – 32.76
Volume4.99M
Market Cap4.09B
P/E (TTM)20.17
Forward P/E0.00
EPS0.92
Dividend Yield2.23%
Beta0.55
50-Day Avg23.66
200-Day Avg25.95

About

ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. It provides semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide, somatostatin, thymopentin, carbetocin, atosiban acetate, exenatide; and leuprorelin, degarelix, cetrorelix, plecanatide, and desmopressin acetate. ChengDu ShengNuo Biotec Co.,Ltd. was founded in 2001 and is based in Chengdu, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Yongjun Wen
  • Employees1.83K
  • HeadquartersNo. 98, Da'an Road, Dayi County, Chengdu, China, 611330, China
  • Websitehttps://www.snbiopharm.com

Leadership

  • Mr. Yongjun WenChairman & GM · b. 1965
  • Mr. Xiaohai YuVice Chairman & Deputy GM · b. 1988
  • Mr. Li WuCFO, Deputy GM & Director · b. 1974
  • Ms. Xiaoli WangDirector and Deputy General Manager · b. 1970
  • Mr. Changliang LuDeputy General Manager · b. 1970
  • Mr. Zhonggang MaDeputy General Manager · b. 1981
  • Yang ShiAccounting Supervisor
  • Ms. Dewen GuoKey Technical Personnel · b. 1974

Financials

Income Statement

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue194.45M277.97M326.74M378.77M386.53M395.72M435.02M456.07M741.34M
Growth (%)-+42.95%+17.54%+15.92%+2.05%+2.38%+9.93%+4.84%+62.55%
Cost of Revenue68.12M87.07M71.56M84.87M110.67M142.39M163.38M201.61M313.97M
Gross Profit126.34M190.91M255.18M293.90M275.86M253.33M271.64M254.46M741.34M
Gross Margin64.97%68.68%78.10%77.59%71.37%64.02%62.44%55.79%100.00%
Operating Expense87.14M156.46M197.63M224.12M200.04M180.49M190.54M192.40M540.50M
Operating Income39.20M34.44M57.55M69.79M75.81M72.84M81.10M62.06M200.84M
Operating Margin20.16%12.39%17.61%18.42%19.61%18.41%18.64%13.61%27.09%
EBITDA52.24M47.81M70.22M86.06M88.60M99.59M116.85M107.12M221.62M
EBITDA Margin26.86%17.20%21.49%22.72%22.92%25.17%26.86%23.49%29.90%
Net Income33.90M29.86M48.13M60.00M61.25M64.48M70.34M50.02M165.82M
Net Income Margin17.43%10.74%14.73%15.84%15.85%16.30%16.17%10.97%22.37%
R&D14.47M15.68M11.10M18.25M13.75M23.29M29.05M49.17M54.91M
R&D as % of Total Revenue7.44%5.64%3.40%4.82%3.56%5.88%6.68%10.78%7.41%
Interest Expense748.71K1.10M786.34K116.18K268.73K3.56M9.08M12.01M15.14M
Interest Expense % of Total Revenue0.39%0.40%0.24%0.03%0.07%0.90%2.09%2.63%2.04%

Balance Sheet

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets348.20M478.25M518.92M592.98M956.62M1.11B1.32B1.65B1.93B
Total Liabilities106.46M150.90M142.46M155.41M171.48M281.27M435.63M729.58M876.93M
Total Equity241.74M327.35M376.46M437.57M785.14M826.74M879.93M918.34M1.06B
Cash36.50M121.31M104.22M129.53M211.56M372.12M219.13M218.71M281.05M
Total Debt15.01M15.36M456.60K-32.89M102.64M226.83M382.19M-
Net Debt-21.49M-105.95M-103.76M-129.53M-178.68M-269.48M7.70M163.48M74.65M

Cash Flow

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow58.22M66.23M30.92M80.84M52.41M95.62M86.53M25.27M178.45M
Investing Cash Flow-35.15M-31.37M-30.02M-51.78M-281.91M20.96M-370.87M-230.83M-
Financing Cash Flow-10.22M48.74M-16.19M-3.64M312.20M42.25M129.75M192.51M-
Capital Expenditure35.15M31.37M30.84M51.96M64.22M135.85M277.98M247.48M145.77M
Free Cash Flow23.07M34.86M75.43K28.89M-11.81M-40.23M-193.20M-222.20M32.68M
Dividends Paid29.05M415.60K401.17K-25.00K24.00M29.18M34.17M36.00M
FCF to OCF39.63%52.64%0.24%35.73%-22.53%-42.07%-223.28%-879.20%18.31%
Dividend Paid to FCF125.88%1.19%531.86%--0.21%-59.65%-15.10%-15.38%110.15%

Earnings

Report DateJun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023
EPS Estimate--------
EPS Actual0.110.170.160.130.040.180.230.13
Surprise--------
Timing--------

Key Statistics & Ratios

Market Cap4.09B
Enterprise Value4.64B
Trailing P/E20.17
Forward P/E0.00
Price / Sales4.49
Price / Book3.80
EPS0.92
Book Value5.19
Revenue (TTM)911.15M
Gross Profit (TTM)520.99M
EBITDA344.74M
Profit Margin22.41%
Operating Margin31.13%
Return on Equity19.11%
Return on Assets8.89%
Shares Outstanding220.34M
Shares Float136.55M
Beta0.55
Dividend Yield2.23%
Dividend Rate0.41
Payout Ratio37.08%

Dividends

20261×
0.32Jun 5, 2026
20252×
0.02Nov 17, 20250.07Jun 13, 2025
20241×
0.10Jun 14, 2024
20231×
0.13Jun 19, 2023
20221×
0.11Jun 1, 2022

Stock Splits

  • Jun 5, 20261.4:1
  • Jun 13, 20251.4:1
  • Jun 19, 20231.4:1